Description: The discovery of the second messengers, cAMP and cGMP, in 1958 led to a deeper understanding of the signal transduction processes behind physiological stimulation and response. Later, the identification of phosphodiesterases (PDEs) and the establishment of their role in diseases led to the development of drugs targeting this class of enzymes. PDEs are a complex superfamily of metallophosphohydrolase enzymes that regulate the activity of second messengers. The superfamily consists of 11 different gene families, ranging from PDE1 to PDE11. These enzymes can be differentiated, in terms of their 3D-structure, modes of regulation, cellular localization and sensitivity to inhibitors.

Until 1998, only non-selective PDE inhibitors were available in the market and were primarily indicated for providing symptomatic relief for respiratory diseases, including COPD and asthma. Post the launch of Viagra® in 1998, several selective PDE inhibitors came into the market. At present, there are 13 PDE inhibitors commercially available in different geographies. Due to the involvement of PDEs in multiple cellular processes, inhibitors against these molecular targets are applicable across a diverse range of disease indications.

It is worth mentioning that the introduction of PDE inhibitors brought a radical change in the treatment of erectile dysfunction. Consequently, these molecules now occupy a major share in the erectile dysfunction market. In addition, PDE inhibitors are also being developed to address the current unmet need for pharmacological interventions for the treatment of patients suffering from certain neurological diseases, cardiovascular diseases, respiratory diseases and dermatological diseases. Drug candidates targeting schizophrenia, atopic dermatitis, Huntington's disease, COPD, asthma and Alzheimer's disease are all in various phases of clinical development.

The success of the marketed PDE inhibitors has prompted several industry players to undertake initiatives in this area. The fragmented nature of the market is expected to increase the pace of innovation; as more molecules advance to late stage development and eventually get commercialized, we expect the new entrants to actively monetize this growing opportunity.

The PDE Inhibitors Market, 2016-2026 study offers a comprehensive analysis of the current landscape of these therapies and an informed opinion on how the field is likely to evolve over the next decade. The market has gained traction during the last few years with many drug candidates designed to address a wide range of diseases. PDE5, with two blockbuster drugs (Viagra® and Cialis®), is one of the most researched PDE inhibitor subtype. In the recent past, another PDE inhibitor subtype, PDE4, has surfaced to address the unmet needs associated with respiratory diseases and dermatological disorders.

Among other things, the report provides the following information:

- A detailed overview of the PDE inhibitors pipeline covering marketed, clinical and preclinical therapies. We have presented information on the respective phases of development, key players involved, PDE inhibitor subtypes, routes of administration and indications being targeted by specific drug candidates.

- Comprehensive profiles highlighting clinical trial details, key clinical results and future market opportunity for the marketed and late stage (phase II and phase III) PDE inhibitors.

- A list of key opinion leaders (KOLs) who have been involved in the discovery and development of PDE inhibitors.

- A discussion on emerging trends and the popularity of PDE inhibitors as observed on social media platforms, such as Twitter, over the last few years.

- A discussion on the potential side effects and the warnings issued by regulatory authorities, indicating areas of improvement for future drug development.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters such as target consumer segments, likely adoption rates and expected pricing, we have provided an estimate of the size of the market in the short-mid-term and long
The base year for the report is 2016. To account for the uncertainties associated with the development of novel therapeutic classes and to add robustness to our model, we have provided three forecast scenarios portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were influenced by discussions with experts in the industry. All figures and technical details presented in the report have been sourced and analyzed from publicly available data. All financial figures mentioned in this report are in USD, unless specified otherwise.

Example Highlights

- Around 40 PDE inhibitors are currently in various stages of clinical/preclinical development. PDE4 and PDE5 inhibitors, each occupying over 30% share of the pipeline, have emerged as the most prominent PDE inhibitor subtypes.

- Several molecules are under development for the treatment of neurological diseases (36%), such as schizophrenia, Alzheimer’s disease and Huntington's disease; most of these molecules are in early development phases. Other key therapeutic areas include genitourinary diseases (25%) and cardiovascular diseases (11%).

- Although the market was initially led by large-size pharma players (such as AstraZeneca, Bayer, Celgene, Eli Lilly, Pfizer), the current market is characterized by the presence of several small/mid-sized pharma players. Notable examples of small firms and start-ups include (in alphabetical order) BioCrea, Dart NeuroScience, Carinopharm, CTC Bio, FORUM Pharmaceuticals, Intra-Cellular Therapies, Omeros Corporation, Medimetriks Pharmaceuticals, NuSirt Biopharma, Palobiotica, Roivant Sciences, Sagene Pharmaceuticals, Tetra Discovery Partners, Tritechbiopharm, VIVUS, Verona Pharma, and tvt Therapeutics.

- Several research institutes, companies and organizations have made significant contribution to the overall development of these therapeutics. During our research, we identified over 400 key opinion leaders who have played critical role in the development of PDE inhibitors. Lee Zane (Anacor Pharmaceuticals/Pfizer), Sae Woong Kim (Catholic University Medical College), Dave Singh (Medicines Evaluation Unit) and Min-Gul Kim (Chonbuk National University Hospital) are some of the well-known researchers who have done exemplary work in this field.

- With the presence of already approved PDE inhibitors such as Viagra® and Cialis®, trends on social media platform have indicated growing trend. In fact, we were able to capture around 2.7 million tweets of relevant keywords over last five years on Twitter.

- It is important to highlight that the impending patent expiries of currently approved drugs is expected to negatively impact the market’s growth in the short-term. However, it is poised to gain momentum post 2021 after the anticipated approval of a number of late stage product candidates. By 2026, we expect that the overall PDE inhibitors market could be worth over USD 10 billion.
4.3. PDE Inhibitors: Pipeline Analysis
4.3.1. PDE Inhibitors: Distribution by Phase of Development
4.3.2. PDE Inhibitors: Distribution by PDE Subtypes
4.3.3. PDE Inhibitors: Distribution by Therapeutic Areas
4.3.4. PDE Inhibitors: Distribution by Route of Administration
4.3.5. PDE Inhibitors: Distribution by Geography
4.3.6. PDE Inhibitors: Leading Players

5. Genitourinary and Cardiovascular Diseases
5.1. Context and Background
5.2. Genitourinary Diseases
5.2.1. Erectile Dysfunction
5.2.1.1. Introduction and Epidemiology
5.2.1.2. Most Prominent PDE Inhibitor Subtypes

5.3.1. Pulmonary Hypertension
5.3.1.1. Introduction and Epidemiology
5.3.1.2. Most Prominent PDE Inhibitor Subtypes

5.4. PDE Inhibitors under Development for Genitourinary Diseases and Cardiovascular Diseases
5.5. Hanmi Pharmaceutical
5.5.1. Company Overview
5.5.2. Financial Performance
5.5.3. PDE Inhibitor Pipeline
5.5.3.1. HGP1207
5.5.3.1.1. Product Overview
5.5.3.1.2. Current Status of Development
5.5.3.1.3. Clinical Trials
5.5.3.2. HCP1303
5.5.3.2.1. Product Overview
5.5.3.2.2. Current Status of Development
5.5.3.2.3. Clinical Trials

5.6. PDE Inhibitors: Trends on Social Media
5.7. Trend on Twitter
5.7.1. Most Popular Marketed Drugs
5.7.2. Most Popular PDE Inhibitor Subtypes
5.7.2.1. Most Popular Keywords (Word Cloud Representation)

6. Neurological Diseases
6.1. Chapter Overview
6.2. Schizophrenia
6.2.1. Introduction and Epidemiology

6.3. Huntington’s Disease
6.3.1. Introduction and Epidemiology
6.3.2. Most Prominent PDE Inhibitor Subtypes

6.4. Alzheimer’s Disease
6.4.1. Introduction and Epidemiology
6.4.2. Most Prominent PDE Inhibitor Subtypes

6.5. PDE Inhibitors under Development for Neurological Diseases
6.6. Boehringer Ingelheim
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. PDE Inhibitor Pipeline
6.6.3.1. BI 409306
6.6.3.1.1. Product Overview
6.6.3.1.2. Current Status of Development
6.6.3.1.3. Clinical Trials
6.6.3.1.4. Key Clinical Trial Results
6.7. Takeda Pharmaceuticals  
6.7.1. Company Overview  
6.7.2. Financial Performance  
6.7.3. PDE Inhibitor Pipeline  
6.7.3.1. TAK-063  
6.7.3.1.1. Product Overview  
6.7.3.1.2. Current Status of Development  
6.7.3.1.3. Clinical Trials  
6.7.3.1.4. Key Clinical Trial Results  

6.8. Pfizer  
6.8.1. Company Overview  
6.8.2. Financial Performance  
6.8.3. PDE Inhibitor Pipeline  
6.8.3.1. PF-02545920  
6.8.3.1.1. Product Overview  
6.8.3.1.2. Current Status of Development  
6.8.3.1.3. Clinical Trials  
6.8.3.1.4. Key Clinical Trial Results  
6.8.4. Collaborations  

6.9. Dart NeuroScience  
6.9.1. Company Overview  
6.9.2. PDE Inhibitor Pipeline  
6.9.2.1. HT-0712/IPL-455903  
6.9.2.1.1. Product Overview  
6.9.2.1.2. Current Status of Development  
6.9.2.1.3. Clinical Trials  
6.9.2.1.4. Key Clinical Trial Results  

6.10. Omeros Corporation  
6.10.1. Company Overview  
6.10.2. Financial Performance  
6.10.3. PDE Inhibitor Pipeline  
6.10.3.1. OMS824  
6.10.3.1.1. Product Overview  
6.10.3.1.2. Current Status of Development  
6.10.3.1.3. Clinical Trials  
6.10.3.1.4. Key Clinical Trial Results  
6.10.4. Collaborations  

7. Dermatological Disorders  
7.1. Chapter Overview  
7.2. Atopic Dermatitis  
7.2.1. Introduction and Epidemiology  
7.2.2. Most Prominent PDE Inhibitor Subtypes  

7.3. Psoriasis  
7.3.1. Introduction and Epidemiology  
7.3.2. Most Prominent PDE Inhibitor Subtypes  

7.4. PDE Inhibitors under Development For Dermatology  
7.5. Anacor Pharmaceuticals (a part of Pfizer)  
7.5.1. Company Overview  
7.5.2. Financial Performance  
7.5.3. PDE Inhibitor Pipeline  
7.5.3.1. Crisaborole/AN2728  
7.5.3.1.1. Product Overview  
7.5.3.1.2. Current Status of Development  
7.5.3.1.3. Clinical Trials  
7.5.3.1.4. Key Clinical Trials  

7.6. Otsuka
8.6.3.1. NS-0200
8.6.3.1.1. Product Overview
8.6.3.1.2. Current Status of Development
8.6.3.1.3. Clinical Trials
8.6.3.1.4. Key Clinical Trial Results

9. KOL Analysis
9.1. Chapter Overview
9.2. Scope and Methodology
9.2.1. PDE Inhibitors: Prominent Researchers
9.2.2. PDE Inhibitors: Leading Key Opinion Leaders

10. Market Opportunity
10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Research Methodology
10.4. Overall PDE Inhibitors Market, 2016-2026
10.4.1. Overall PDE Inhibitors Market: Distribution by Therapeutic Area
10.4.2. Overall PDE Inhibitors Market: Distribution by PDE Subtype
10.5. Daliresp® (AstraZeneca)
10.5.1. Target Patient Population
10.5.2. Sales Forecast
10.6. OTEZLA® (Celgene)
10.6.1. Target Patient Population
10.6.2. Sales Forecast
10.7. Crisaborole (Anacor Pharmaceuticals)
10.7.1. Target Patient Population
10.7.2. Sales Forecast
10.8. OPA-15406/MM36 (Otsuka Pharmaceutical/Medimetriks Pharmaceuticals)
10.8.1. Target Patient Population
10.8.2. Sales Forecast
10.9. HT-0712 (Dart NeuroScience)
10.9.1. Target Patient Population
10.9.2. Sales Forecast
10.10. RPL554 (Verona Pharma)
10.10.1. Target Patient Population
10.10.2. Sales Forecast
10.11. BI409306 (Boehringer Ingelheim)
10.11.1. Target Patient Population
10.11.2. Sales Forecast
10.12. NS-0200 (NuSirt Biopharma)
10.12.1. Target Patient Population
10.12.2. Sales Forecast
10.13. RVT-501 (Roivant Sciences)
10.13.1. Target Patient Population
10.13.2. Sales Forecast
10.14. CHF6001 (Chiesi Farmaceutici)
10.14.2. Sales Forecast
10.15. PF-02545920 (Pfizer)
10.15.1. Target Patient Population
10.15.2. Sales Forecast
10.16. TAK-063 (Takeda Pharmaceutical)
10.16.1. Target Patient Population
10.16.2. Sales Forecast

10.17. OMS824 (Omeros Corporation)
10.17.1. Target Patient Population
10.17.2. Sales Forecast

11. Discontinued Molecules and Side Effects
11.1. Chapter Overview
11.2. Discontinued Molecules
11.2.1. Discontinued/Terminated Molecules: Distribution by Phase of Development
11.2.2. Discontinued/Terminated Molecules: Distribution by PDE Subtype
11.3. Precautionary Notes and Common Side Effects
11.3.1. PDE5 Inhibitors
11.3.2. PDE4 Inhibitors

12. Conclusion
12.1. The Pipeline Is Dominated By the Presence of PDE4, PDE5 and PDE10 Inhibitors
12.2. Both Big and Small Pharma Players, Keen to Leverage the Broad Spectrum Applicability of This Drug Class, are Actively Involved
12.3. Involvement of Several Prominent Researchers in This Domain and Growing Social Media Chatter Are Indicative of the Popularity of This Drug Class
12.4. Varying Opportunity across Disease Indications is Likely to Translate into a Lucrative Future Growth Potential

13. Interview Transcripts

14. Appendix: Tabulated Data
15. Appendix: List of Companies and Research Organizations

List of Figures

Figure 3.1 Schematic Representation of Phosphodiesterases
Figure 3.2 PDE Isozymes: Function
Figure 4.1 PDE Inhibitors: Distribution by Phase of Development (Marketed/ Phase III/Phase II/Phase I/Preclinical/Discovery)
Figure 4.2 PDE Inhibitors: Distribution by PDE Subtypes
Figure 4.3 PDE Inhibitors: Distribution by PDE Subtypes and Phase of Development
Figure 4.4 PDE Inhibitors: Distribution by Therapeutic Areas
Figure 4.5 PDE Inhibitors: Distribution by Key Therapeutic Indications
Figure 4.6 PDE Inhibitors: Distribution by PDE Subtype, Therapeutic Area and Phase of Development
Figure 4.7 PDE Inhibitors: Distribution by Route of Administration
Figure 4.8 PDE Inhibitors: Distribution by Geography
Figure 4.9 PDE Inhibitors: Regional Landscape
Figure 4.10 PDE Inhibitors: Leading Players
Figure 5.1 Hanmi Science Holding: Annual Revenues, 2011 - H1 2016 (KRW Billion)
Figure 5.2 PDE Inhibitors: Most Popular Marked Drugs on Twitter, 2010-2015
Figure 5.3 PDE Inhibitors: Most Popular PDE Inhibitor Subtypes on Twitter, 2010-2015
Figure 5.4 PDE Inhibitors: Most Popular Keywords on Twitter, 2010-2015
Figure 6.1 Boehringer Ingelheim: Annual Revenues, 2010-2015 (EUR Billion)
Figure 6.2 Boehringer Ingelheim: Revenues Distribution by Business Segments, 2015 (EUR Billion)
Figure 6.3 Takeda Pharmaceuticals: Annual Revenues, 2010-Q1 2016 (JPY Billion)
Figure 6.4 Takeda Pharmaceuticals: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Figure 6.5 Pfizer: Annual Revenues, 2011 - H1 2016 (USD Billion)
Figure 6.6 Pfizer: Revenue Distribution by Business Segments, 2015 (USD Billion)
Figure 6.7 Omeros Corporation: Annual Revenues, 2011 - H1 2016 (USD Million)
Figure 6.8 Omeros Corporation: Funding Instances (USD Million)
Figure 7.1 Anacor Pharmaceuticals: Annual Revenues, 2011 - Q1 2016 (USD Million)
Figure 7.2 Otsuka: Annual Revenues, 2011-H1 2016 (JPY Billion)
Figure 7.3 Otsuka: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Figure 8.1 Chiesi Farmaceutici: Annual Revenues, 2010-2015 (EUR Billion)
Figure 8.2 Verona Pharma: Funding Instances (GBP Million)
Figure 8.3 NuSirt Biopharma: Funding Instances (USD Million)
Figure 9.1 PDE Inhibitors: Mapping Prominent Researchers
Figure 9.2 PDE Inhibitors: Leading Key Opinion Leaders
Figure 10.1 Overall PDE Inhibitors Market, 2016-2026, Base Scenario (USD Million)
Figure 10.2 Overall PDE Inhibitors Market: Distribution by Therapeutic Area, 2016-2026 (USD Million)
Figure 10.3 Evolution of PDE Inhibitors Market: Distribution by Therapeutic Area 2016, 2021, 2026 (Base Scenario)
Figure 10.4 Overall PDE Inhibitors Market: Distribution by PDE Subtype, 2016-2026 (USD Million)
Figure 10.5 Evolution of PDE Inhibitors Market: Distribution by PDE Subtype 2016, 2021, 2026 (Base Scenario)
Figure 10.6 Daliresp Sales Forecast, Base Scenario (USD Million)
Figure 10.7 OTEZLA Sales Forecast, Base Scenario (USD Million)
Figure 10.8 Crisaborole Sales Forecast, Base Scenario (USD Million)
Figure 10.9 OPA-15406 Sales Forecast, Base Scenario (USD Million)
Figure 10.10 HT-0712 Sales Forecast, Base Scenario (USD Million)
Figure 10.11 RPL554 Sales Forecast, Base Scenario (USD Million)
Figure 10.12 BI409306 Sales Forecast, Base Scenario (USD Million)
Figure 10.13 NS-0200 Sales Forecast, Base Scenario (USD Million)
Figure 10.14 RVT-501 Sales Forecast, Base Scenario (USD Million)
Figure 10.15 CHF6001 Sales Forecast, Base Scenario (USD Million)
Figure 10.16 PF-02545920 Sales Forecast, Base Scenario (USD Million)
Figure 10.17 TAK-063 Sales Forecast, Base Scenario (USD Million)
Figure 10.18 OMS824 Sales Forecast, Base Scenario (USD Million)
Figure 11.1 Discontinued/Terminated Molecules: Distribution by Phase of Termination
Figure 11.2 Discontinued/Terminated Molecules: Distribution by PDE Subtype
Figure 12.1 PDE Inhibitors: Developer Landscape
Figure 12.2 PDE Inhibitors: Key Indications
Figure 12.3 PDE Inhibitors: Market Opportunity across Different Disease Indications
Figure 12.4 PDE Inhibitors Market: Conservative, Base and Optimistic Forecast Scenarios, 2016-2026 (USD Billion)

List of Tables

Table 3.1 PDE Superfamily
Table 3.2 Non-selective PDE Inhibitors
Table 4.1 PDE Inhibitors: Marketed and Developmental Pipeline
Table 4.2 PDE Inhibitors: Unknown Status
Table 5.1 PDE Inhibitors: Genitourinary and Cardiovascular Diseases
Table 5.2 Hanmi Pharmaceuticals: PDE Inhibitor Pipeline
Table 5.3 HGP1207: Current Status of Development
Table 5.4 HGP1207: Clinical Trials
Table 5.5 HCP1303: Current Status of Development
Table 5.6 HCP1303: Clinical Trials
Table 6.1 PDE Inhibitors Pipeline: Neurological Diseases
Table 6.2 Boehringer Ingelheim: PDE Inhibitor Pipeline
Table 6.3 BI 409306: Current Status of Development
Table 6.4 BI 409306: Clinical Trials
Table 6.5 BI 409306: Clinical Trial Results (NCT01505894)
Table 6.6 BI 409306: Clinical Trial Results (NCT01611311)
Table 6.7 Takeda Pharmaceuticals: PDE Inhibitor Pipeline
Table 6.8 TAK-063: Current Status of Development
Table 6.9 TAK-063: Clinical Trials
Table 6.10 Pfizer: PDE Inhibitor Pipeline
Table 6.11 PF-02545920: Current Status of Development
Table 6.12 PF-02545920: Clinical Trials
Table 6.13 Dart Neuroscience: PDE Inhibitor Pipeline
Table 6.14 HT-0712: Current Status of Development
Table 6.15 HT-0712: Clinical Trials
Table 6.16 Omeros Corporation: PDE Inhibitor Pipeline
Table 6.17 OMS824: Current Status of Development
Table 6.18 OMS824: Clinical Trials
Table 7.1 PDE Inhibitors Pipeline: Dermatological Disorders
Table 7.2 Anacor Pharmaceuticals: PDE Inhibitors Pipeline
Table 14.23 NuSirt Biopharma: Funding Instances (USD Million)
Table 14.24 Overall PDE Inhibitors Market, 2016-2026, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.25 Overall PDE Inhibitors Market: Distribution by Therapeutic Area, 2016-2026 (USD Million)
Table 14.26 Overall PDE Inhibitors Market: Distribution by PDE Subtype, 2016-2026 (USD Million)
Table 14.27 Daliresp Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.28 OTEZLA Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.29 Crisaborole Sales Forecast, Base Scenario (USD Million)
Table 14.30 OPA-15406 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.31 HT-0712 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.32 RPL554 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.33 BI409306 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.34 NS-0200 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.35 RVT-501 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.36 CHF6001 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.37 PF-02545920 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.38 TAK-063 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.39 OMS824 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.40 Discontinued/Terminated Molecules: Distribution by Phase of Termination
Table 14.41 Discontinued/Terminated Molecules: Distribution by PDE Subtype

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>PDE Inhibitors Market, 2016-2026</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3943429/">http://www.researchandmarkets.com/reports/3943429/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>□</td>
<td>USD 2349</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>□</td>
<td>USD 5499</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>□</td>
<td>USD 9999</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
Mr □  Mrs □  Dr □  Miss □  Ms □  Prof □  
First Name: ____________________________  Last Name: ____________________________

Email Address: * ____________________________

Job Title: ____________________________

Organisation: ____________________________

Address: ____________________________

City: ____________________________

Postal / Zip Code: ____________________________

Country: ____________________________

Phone Number: ____________________________

Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World